AMRX vs MANE: stock comparison and AI forecast
Amneal Pharmaceuticals, Inc. (AMRX) and Veradermics, Inc (MANE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AMRX Amneal Pharmaceuticals, Inc.
- Market Cap
- $6.93B
- P/E Ratio
- 144.7x
- Size
- mid-cap
- AI Forecast
MANE Veradermics, Inc
- Price
- $148.44 +42.9% · 6M
- Market Cap
- $6.20B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- AMRX is 1.1 times larger than MANE by market capitalization ($6.93B against $6.20B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AMRX | MANE |
|---|---|---|
| Market Cap | $6.93B | $6.20B |
| P/E Ratio | 144.74x | – |
| P/B Ratio | – | 7.79x |
| EPS | $0.15 | $-30.38 |
| Book Value/Share | – | $19.06 |
| Revenue/Share | $10.01 | – |
| FCF/Share | $0.28 | $-1.84 |
Profitability & Margins
| Metric | AMRX | MANE |
|---|---|---|
| ROIC | – | -13.3% |
| Gross Margin | 40.2% | – |
| Tax Rate | 5.4% | 0.0% |
Financial Health
| Metric | AMRX | MANE |
|---|---|---|
| Current Ratio | 1.87x | 77.68x |
| Quick Ratio | 1.24x | – |
| D/E Ratio | – | 0.01x |
| Financial Leverage | – | 1.01x |
| Interest Coverage | 1.6x | – |
| Working Capital | $975M | $795M |
Cash Flow
| Metric | AMRX | MANE |
|---|---|---|
| Operating Cash Flow | $181M | -$76M |
| Free Cash Flow | $88M | -$77M |
| Capital Spending | -$92M | -$370K |
| OCF Growth YoY | -44.9% | – |
| FCF Growth YoY | -66.6% | – |
| FCF/Sales | 2.8% | – |
| CapEx/Sales | 2.9% | – |
Operational Efficiency
| Metric | AMRX | MANE |
|---|---|---|
| Inventory Turnover | 2.7x | – |
| Fixed Assets Turnover | 5.6x | – |
| Days Inventory | 135 days | – |
Income Statement
| Metric | AMRX | MANE |
|---|---|---|
| Total Revenue | $3.20B | – |
| Operating Income | $479M | -$106M |
| Net Income | $0.00M | – |
| R&D Expense | $181M | $71M |
| SG&A Expense | $574M | – |
| Cost of Goods Sold | $1.91B | – |
Dividend & Shareholder Information
| Metric | AMRX | MANE |
|---|---|---|
| Shares Outstanding | 319M | 42M |
AMRX vs MANE: stock comparison and AI forecast
Which is bigger, AMRX or MANE?
AMRX is 1.1 times larger than MANE by market capitalization ($6.93B against $6.20B).
Which one does Intratio's AI model rank higher, AMRX or MANE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.